Displaying 5 studies

  • Tissue Remodeling in Adenomyosis Pathophysiology Rochester, MN

    The aims of this study are to delineate expression of a novel REST-miRNA mediated tissue remodeling pathway in adenomyosis and define its function using novel experimental mouse models, and to delineate REST-miR-137-3p (A) and REST-miR-29b-3p (B) mediators and mechanisms relevant to adenomyosis pathophysiology.

    Adenomyosis is a nonmalignant uterine disease characterized by endometrial stroma and glands found within the myometrium.1 Adenomyosis has been associated with heavy and painful menstrual periods, pelvic pain, pain with intercourse, and reproductive dysfunction. However, now that imaging is identifying adenomyosis in younger and more varied women than those electing hysterectomy where pathological diagnosis occurred, many of our assumptions about the clinical ...

  • Vaginal Bromocriptine for Treatment of Adenomyosis Rochester, MN; Rochester, MN

    Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms including heavy menstrual bleeding and pelvic pain. The only widely accepted treatment for adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine, as a therapy based on animal models of the disease and our prior clinical research to observe any objective improvement in the extent of the disease using Magnetic Resonance Imaging (MRI)and standard measurements for other gynecologic diseases to measure symptomatology.

  • A Study of Endometriosis Biomarkers Scottsdale/Phoenix, AZ

    The purpose of this study is to analytically validate a cluster of specific biomarkers for endometriosis diagnosis and disease recurrence. This signature will be tested on endometrium and blood from 975 patients, divided in two groups : 550 patients affected by endometriosis and 225 patients unaffected (controls). EndoSearch is not about drug or medical device assessment but a research study for biomarker analytical validation purpose.

  • Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps Rochester, MN

    This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer overtime. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.

  • Microbiome Role in Non-Cancerous Reproductive Tract Disorders Rochester, MN

    The aim is the characterization of the microbiome of subjects experiencing benign reproductive tract disorders and its comparison to the microbiome present in individuals lacking that disorder.


Mayo Clinic Footer